EGFR and breast carcinoma: Of the chosen gene signatures, MYO1D has been found to have increased expression levels in breast cancer and has the capacity to upregulate the expression of the Epidermal Growth Factor Receptor (EGFR), which improves the motility and viability of colorectal and breast cancer cells (Ko et al. 2019).